Literature DB >> 17951512

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.

Duane A Mitchell1, Weihua Xie, Robert Schmittling, Chris Learn, Allan Friedman, Roger E McLendon, John H Sampson.   

Abstract

Human cytomegalovirus (HCMV) has been described to be associated with several human malignancies, though the frequency of detection remains controversial. It is unclear whether HCMV plays an active role in malignant tumor progression or becomes reactivated under pathologic conditions that result in chronic inflammation or immunosuppression. In this study, we report on the investigation of detecting HCMV in the tumors and peripheral blood of patients with newly diagnosed glioblastoma multiforme (GBM). Using immunohistochemistry, in situ hybridization, and polymerase chain reaction amplification of viral DNA, the detection of HCMV was investigated in tumor and blood specimens from patients with GBM as well as in the peripheral blood of normal volunteers and patients undergoing craniotomy for diagnoses other than GBM. We found that a high percentage (>90%) of GBM tumors, not surrounding normal brain, are associated with HCMV nucleic acids and proteins. Furthermore, a significant proportion of patients (80%) with newly diagnosed GBM have detectable HCMV DNA in their peripheral blood, while sero-positive normal donors and other surgical patients did not exhibit detectable virus, suggesting either a systemic reactivation of HCMV within patients with GBM or shedding of viral DNA from infected tumor cells into the periphery. These results confirm the association of HCMV with malignant gliomas and demonstrate that subclinical HCMV viremia (presence of viral DNA in blood without clinical symptoms of infection) is a previously unrecognized disease spectrum in patients with GBM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951512      PMCID: PMC2600830          DOI: 10.1215/15228517-2007-035

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  50 in total

Review 1.  Clinical aspects and management of cytomegalovirus infection.

Authors:  J G P Sissons; A J Carmichael
Journal:  J Infect       Date:  2002-02       Impact factor: 6.072

Review 2.  Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency.

Authors:  Mariana G Bego; Stephen St Jeor
Journal:  Exp Hematol       Date:  2006-05       Impact factor: 3.084

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 4.  Immune evasion by cytomegalovirus--survival strategies of a highly adapted opportunist.

Authors:  H Hengel; W Brune; U H Koszinowski
Journal:  Trends Microbiol       Date:  1998-05       Impact factor: 17.079

5.  Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.

Authors:  Abdel-Rahman N Zekri; Waleed S Mohamed; Mohamed A Samra; Ghada M Sherif; Amal M R El-Shehaby; Manal H El-Sayed
Journal:  Transpl Immunol       Date:  2004-12       Impact factor: 1.708

Review 6.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

Review 7.  Human cytomegalovirus: a review of developments between 1970 and 1976. Part II. Experimental developments.

Authors:  S Michelson-Fiske
Journal:  Biomedicine       Date:  1977-04

8.  Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer.

Authors:  Lualhati Harkins; Andrea L Volk; Minu Samanta; Ivan Mikolaenko; William J Britt; Kirby I Bland; Charles S Cobbs
Journal:  Lancet       Date:  2002-11-16       Impact factor: 79.321

9.  Human herpes viruses in non-melanoma skin cancers.

Authors:  A Zafiropoulos; E Tsentelierou; K Billiri; D A Spandidos
Journal:  Cancer Lett       Date:  2003-07-30       Impact factor: 8.679

10.  Elution of cytomegalovirus antibodies from adenocarcinoma of the colon.

Authors:  A Grail; M Norval
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

View more
  190 in total

Review 1.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 2.  Immunotherapy approaches for malignant glioma from 2007 to 2009.

Authors:  Laura A Johnson; John H Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 3.  The role of cytomegalovirus in angiogenesis.

Authors:  Patrizia Caposio; Susan L Orloff; Daniel N Streblow
Journal:  Virus Res       Date:  2010-10-01       Impact factor: 3.303

4.  Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Authors:  Alexia Ghazi; Aidin Ashoori; Patrick J Hanley; Vita S Brawley; Donald R Shaffer; Yvonne Kew; Suzanne Z Powell; Robert Grossman; Zakaria Grada; Michael E Scheurer; Meenakshi Hegde; Ann M Leen; Catherine M Bollard; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk; Nabil Ahmed
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

5.  Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.

Authors:  Arun Kapoor; Hongyi Cai; Michael Forman; Ran He; Meir Shamay; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

6.  Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities.

Authors:  Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol
Journal:  J Neurosci       Date:  2017-06-19       Impact factor: 6.167

7.  Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics.

Authors:  Peter Baumgarten; Martin Michaelis; Florian Rothweiler; Tatjana Starzetz; Holger F Rabenau; Annemarie Berger; Lukas Jennewein; Anne K Braczynski; Kea Franz; Volker Seifert; Joachim P Steinbach; Regina Allwinn; Michel Mittelbronn; Jindrich Cinatl
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.

Authors:  Robert M Prins; Timothy F Cloughesy; Linda M Liau
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

10.  Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

Authors:  Christine E Brown; Renate Starr; Catalina Martinez; Brenda Aguilar; Massimo D'Apuzzo; Ivan Todorov; Chu-Chih Shih; Behnam Badie; Michael Hudecek; Stanley R Riddell; Michael C Jensen
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.